Auswahl der wissenschaftlichen Literatur zum Thema „G4 stabilization“

G-quadruplexes (G4s) are noncanonical DNA secondary structures formed through the self-association of guanines, and G4s are distributed widely across the genome. G4 participates in multiple biological processes including gene transcription, and G4-targeted ligands serve as potential therapeutic agents for DNA-targeted therapies. However, genome-wide studies of the exact roles of G4s in transcriptional regulation are still lacking. Here, we establish a sensitive G4-CUT&Tag method for genome-wide profiling of native G4s with high resolution and specificity. We find that native G4 signals are cell type–specific and are associated with transcriptional regulatory elements carrying active epigenetic modifications. Drug-induced promoter-proximal RNA polymerase II pausing promotes nearby G4 formation. In contrast, G4 stabilization by G4-targeted ligands globally reduces RNA polymerase II occupancy at gene promoters as well as nascent RNA synthesis. Moreover, ligand-induced G4 stabilization modulates chromatin states and impedes transcription initiation via inhibition of general transcription factors loading to promoters. Together, our study reveals a reciprocal genome-wide regulation between native G4 dynamics and gene transcription, which will deepen our understanding of G4 biology toward therapeutically targeting G4s in human diseases.

Abstract Loss of function mutations in α-thalassaemia/mental retardation X-linked (ATRX) are a critical molecular hallmark for invariably fatal high-grade glioma (HGG). Mutational inactivation of histone chaperone ATRX leads to accumulations of abnormal DNA secondary structures known as G-quadruplexes (G4s), thereby inducing replication stress and DNA damage. As G4s arise at GC-rich regions (i.e., pericentromeric and telomeric regions), ATRX-deficiency alters genome-wide accessibility of chromatin, leads to transcriptional dysregulation, and induces alternative lengthening of telomeres (ALT). Our goal is to target ATRX deficiency through G4 stabilizers, which represent a class of novel small molecule compounds that selectively bind to and stabilize G4 structures. However, the genomic consequences and efficacy of this therapy for ATRX-deficient HGG are poorly understood. We therefore sought to evaluate the molecular mechanisms that drive selective lethality in patient-derived ATRX-deficient glioma stem cells (GSCs), following G4 stabilization. We found that ATRX-deficient GSCs demonstrate dose-dependent enhanced sensitivity to G4 stabilization, compared to ATRX-intact controls. Cell viability assays confirmed the specificity of our G4 stabilizer in comparison to other commonly used G4 stabilizers. Interestingly, G4 stabilization activated p53-independent apoptosis in ATRX-deficient GSCs. Furthermore, ATRX-deficient GSCs exhibit upregulated expression of both ATR and ATM pathways upon G4 stabilization, indicating enhanced replication stress and DNA damage via double-stranded breaks, respectively. Our preliminary findings suggest that ATR and ATM activation leads to the inhibition of transcription factor NF-κB, which in turn drives apoptosis. Lastly, our data indicate that G4 stabilization perturbs the ALT phenotype in ATRX-deficient GSCs, likely contributing to telomeric dysfunction. Taken together, these findings suggest that G4 stabilizers could synergize with ionizing radiation, the standard of care, as they are both DNA-damaging therapies. Our work defines mechanisms of action and efficacy of a novel therapeutic strategy for ATRX-deficient HGG, with strong implications for other ATRX-deficient cancers.

G-quadruplexes (G4) are the most actively studied non-canonical secondary structures formed by contiguous repeats of guanines in DNA or RNA strands. Small molecule mediated targeting of G-quadruplexes has emerged as an attractive tool for visualization and stabilization of these structures inside the cell. Limited number of DNA and RNA G4-selective assays have been reported for primary ligand screening. A combination of fluorescence spectroscopy, AFM, CD, PAGE, and confocal microscopy have been used to assess a dimeric carbocyanine dye B6,5 for screening G4-binding ligands in vitro and in cellulo. The dye B6,5 interacts with physiologically relevant DNA and RNA G4 structures, resulting in fluorescence enhancement of the molecule as an in vitro readout for G4 selectivity. Interaction of the dye with G4 is accompanied by quadruplex stabilization that extends its use in primary screening of G4 specific ligands. The molecule is cell permeable and enables visualization of quadruplex dominated cellular regions of nucleoli using confocal microscopy. The dye is displaced by quarfloxin in live cells. The dye B6,5 shows remarkable duplex to quadruplex selectivity in vitro along with ligand-like stabilization of DNA G4 structures. Cell permeability and response to RNA G4 structures project the dye with interesting theranostic potential. Our results validate that B6,5 can serve the dual purpose of visualization of DNA and RNA G4 structures and screening of G4 specific ligands, and adds to the limited number of probes with such potential.

Modulating the expression or function of the enigmatic MYC protein has demonstrated efficacy in an array of cancer types and a marked potential therapeutic index and safety profile. Despite its high therapeutic value, specific and selective inhibitors or downregulating therapeutics have proven difficult to develop. In the current study, we expanded our work on a MYC promoter G-quadruplex (G4) stabilizing DNA clamp to develop an oligonucleotide interfering DNA (DNAi) therapeutic. We explored six DNAi for G4-stabilization through EMSA, DMS footprinting, and thermal stability studies, focusing on the DNAi 5T as the lead therapeutic. 5T, but not its scramble control 5Tscr, was then shown to enter the nucleus, modulate cell viability, and decrease MYC expression through G4-stabilization. DNAi 5T is thus described to be our lead DNAi, targeting MYC regulation through stabilization of the higher-order DNA G4 structure in the proximal promoter, and it is poised for further preclinical development as an anticancer therapeutic.

Abstract Gliomas are the most common primary malignant brain tumor in adults and mutational inactivation of histone chaperone ATRX is a critical molecular marker in the classification of high-grade glioma (HGG). ATRX loss occurs with concurrent mutations in TP53 and IDH1/2, altering genome-wide accessibility of chromatin and inducing replication stress and DNA damage via accumulations of abnormal G-quadruplex (G4) DNA secondary structures. While G4 stabilizers in particular hold strong therapeutic promise, the genomic consequences and efficacy of this treatment are poorly understood. We previously showed that chemical stabilization of G4s in ATRX-deficient normal human astrocytes (NHAs) results in lethality due to induction of replication stress, but it is unknown what drives this lethality in ATRX-deficient patient-derived preclinical models. We therefore sought to evaluate the mechanisms that underlie cell death in ATRX- and p53-deficient preclinical in vitro models following G4 stabilization. We found that ATRX-deficient glioma stem cells (GSCs) demonstrated dose-dependent enhanced sensitivity to G4 stabilization, compared to ATRX-intact controls. Evaluation of cell death mechanisms following G4 stabilization revealed a significant increase in cleaved caspase 3 expression and no p21 expression in ATRX-deficient GSCs, suggesting p53-independent apoptotic activation. Cell cycle flow analysis demonstrated G2/M checkpoint arrest in ATRX-deficient GSCs upon G4 stabilization, suggesting that p53 is nonfunctional at the G1/S checkpoint. Our preliminary findings now suggest that p73, a functional and structural homologue of p53, is activated and drives apoptosis in these ATRX-deficient GSCs. Furthermore, ATRX-deficient GSCs demonstrated upregulated expression of both pATR/pChk1 and pATM/pChk2, indicating enhanced replication stress and DNA damage via double-stranded breaks, respectively. These findings indicate that G4 stabilizers could potentially synergize with ionizing radiation, the current standard of care, as both therapies are DNA-damaging. Taken together, this study elucidates mechanisms of cytotoxicity and efficacy of a novel therapeutic strategy in ATRX-deficient preclinical models.

Green fluorescent protein (GFP) chromophore and its congeners draw significant attention mostly for bioimaging purposes. In this work we probed these compounds as antiviral agents. We have chosen LTR-III DNA G4, the major G-quadruplex (G4) present in the long terminal repeat (LTR) promoter region of the human immunodeficiency virus-1 (HIV-1), as the target for primary screening and designing antiviral drug candidates. The stabilization of this G4 was previously shown to suppress viral gene expression and replication. FRET-based high-throughput screening (HTS) of 449 GFP chromophore-like compounds revealed a number of hits, sharing some general structural features. Structure-activity relationships (SAR) for the most effective stabilizers allowed us to establish structural fragments, important for G4 binding. Synthetic compounds, developed on the basis of SAR analysis, exhibited high LTR-III G4 stabilization level. NMR spectroscopy and molecular modeling revealed the possible formation of LTR-III G4-ligand complex with one of the lead selective derivative ZS260.1 positioned within the cavity, thus supporting the LTR-III G4 attractiveness for drug targeting. Selected compounds showed moderate activity against HIV-I (EC50 1.78–7.7 μM) in vitro, but the activity was accompanied by pronounced cytotoxicity.

In mammalian cells, telomerase transcribes telomeres in large G-rich non-coding RNA, known as telomeric repeat-containing RNA (TERRA), which folds into noncanonical nucleic acid secondary structures called G-quadruplexes (G4s). Since TERRA G4 has been shown to be involved in telomere length and translation regulation, it could provide valuable insight into fundamental biological processes, such as cancer growth, and TERRA G4 binders could represent an innovative strategy for cancer treatment. In this work, the three best candidates identified in our previous virtual screening campaign on bimolecular DNA/RNA G4s were investigated on the monomolecular Tel DNA and TERRA G4s by means of molecular modelling simulations and in vitro and in cell analysis. The results obtained in this work highlighted the stabilizing power of all the three candidates on TERRA G4. In particular, the two compounds characterized by a chromene scaffold were selective TERRA G4 binders, while the compound with a naphthyridine core acted as a dual Tel/TERRA G4-binder. A biophysical investigation by circular dichroism confirmed the relative stabilization efficiency of the compounds towards TERRA and Tel G4s. The TERRA G4 stabilizing hits showed good antiproliferative activity against colorectal and lung adenocarcinoma cell lines. Lead optimization to increase TERRA G4 stabilization may provide new powerful tools against cancer.

The Myc oncogene is overexpressed in many cancers, yet targeting it for cancer therapy has remained elusive. One strategy for inhibition of Myc expression is through stabilization of the G-quadruplex (G4), a G-rich DNA secondary structure found within the Myc promoter; stabilization of G4s has been shown to halt transcription of downstream gene products. Here we used the Automated Ligand Identification System (ALIS), an affinity selection–mass spectrometry method, to identify compounds that bind to the Myc G4 out of a pool of compounds that had previously been shown to inhibit Myc expression in a reporter screen. Using an ALIS-based screen, we identified hits that bound to the Myc G4, a small subset of which bound preferentially relative to G4s from the promoters of five other genes. To determine functionality and specificity of the Myc G4-binding compounds in cell-based assays, we compared inhibition of Myc expression in cells with and without Myc G4 regulation. Several compounds inhibited Myc expression only in the Myc G4-containing line, and one compound was verified to function through Myc G4 binding. Our study demonstrates that ALIS can be used to identify selective nucleic acid-binding compounds from phenotypic screen hits, increasing the pool of drug targets beyond proteins.

Topoisomerase (Topo) inhibitors have long been known as clinically effective drugs, while G-quadruplex (G4)-targeting compounds are emerging as a promising new strategy to target tumor cells and could support personalized treatment approaches in the near future. G-quadruplex (G4) is a secondary four-stranded DNA helical structure constituted of guanine-rich nucleic acids, and its stabilization impairs telomere replication, triggering the activation of several protein factors at telomere levels, including Topos. Thus, the pharmacological intervention through the simultaneous G4 stabilization and Topos inhibition offers a new opportunity to achieve greater antiproliferative activity and circumvent cellular insensitivity and resistance. In this line, dual ligands targeting both Topos and G4 emerge as innovative, efficient agents in cancer therapy. Although the research in this field is still limited, to date, some chemotypes have been identified, showing this dual activity and an interesting pharmacological profile. This paper reviews the available literature on dual Topo inhibitors/G4 stabilizing agents, with particular attention to the structure–activity relationship studies correlating the dual activity with the cytotoxic activity.

Aims The aim of this study was to identify the effect of the manufacturing characteristics of polyethylene acetabular liners on the survival of cementless and hybrid total hip arthroplasty (THA). Methods Prospective cohort study using linked National Joint Registry (NJR) and manufacturer data. The primary endpoint was revision for aseptic loosening. Cox proportional hazard regression was the primary analytical approach. Manufacturing variables included resin type, crosslinking radiation dose, terminal sterilization method, terminal sterilization radiation dose, stabilization treatment, total radiation dose, packaging, and face asymmetry. Total radiation dose was further divided into G1 (no radiation), G2 (> 0 Mrad to < 5 Mrad), G3 (≥ 5 Mrad to < 10 Mrad), and G4 (≥ 10 Mrad). Results A total of 5,329 THAs were revised, 1,290 of which were due to aseptic loosening. Total radiation dose, face asymmetry, and stabilization treatments were found to significantly affect implant survival. G1 had the highest revision risk for any reason and for aseptic loosening and G3 and G4 the lowest. Compared with G1, the adjusted hazard ratio for G2 was 0.74 (95% confidence interval (CI) 0.64 to 0.86), G3 was 0.36 (95% CI 0.30 to 0.43), and G4 was 0.38 (95% CI 0.31 to 0.47). The cumulative incidence of revision for aseptic loosening at 12 years was 0.52 and 0.54 per 100 THAs for G3 and G4, respectively, compared with 1.95 per 100 THAs in G1. Asymmetrical liners had a lower revision risk due to aseptic loosening and reasons other than aseptic loosening compared with symmetric (flat) liners. In G3 and G4, stabilization with vitamin E and heating above melting point performed best. Conclusion Polyethylene liners with a total radiation dose of ≥ 5 Mrad, an asymmetrical liner face, and stabilization with heating above the melting point demonstrate best survival. Cite this article: Bone Joint J 2020;102-B(1):90–101

Les cancers du sein triple négatifs et du pancréas sont associés à de faible taux de survie, dû à leur forte résistance aux traitements conventionnels, constituant un réel problème de santé publique et rendant le développement de nouvelles thérapies ciblées crucial. Au niveau des séquences télomériques et des promoteurs d'oncogènes comme cMYC, cKIT et BCL2, les séquences riches en guanines peuvent former des structures secondaires non conventionnelles, appelées G-quadruplexes. Ces structures jouent un rôle important dans la régulation de l'expression génique, constituant ainsi de prometteuses cibles thérapeutiques pour la lutte contre le cancer.Ici, nous avons choisi une approche pluridisciplinaire, alliant synthèse chimique, chimie théorique, et biologie cellulaire et moléculaire, afin d'identifier de nouveaux composés stabilisant ces structures, dans le but de contrôler la prolifération des cellules cancéreuses. Notre laboratoire a précédemment montré l'intérêt des complexes métalliques symétriques et planaires dans la stabilisation spécifique des G-quadruplexes. Ainsi, nous avons synthétisé 12 nouveaux complexes à base des métaux de transition Zn2+, Ni2+, Cu2+, Pd2+ et Pt2+. Leur capacité à sélectivement stabiliser les G-quadruplexes, en comparaison avec l'ADN double brin, a été démontré et des simulations de dynamique moléculaire révèlent un mode d'interaction peu conventionnel, impliquant la boucle du G-quadruplex.Nos composés induisent la formation de G-quadruplexes au sein des lignées cellulaires cancéreuses, entrainant une régulation à la baisse de nombreux oncogènes comme kRAS, RET et cMYC. Cette répression entraine une réduction de la prolifération et la viabilité des cellules cancéreuses, mais n'affecte que peu les cellules saines.Alors que certains composés induisent la mort des cellules cancéreuses par apoptose sans affecter les cellules saines, et inhibent drastiquement l'expression des oncogènes hRAS et cMYC, d'autres complexes causent des dommages à l'ADN dans les cellules néoplasiques pancréatiques T3M4. Aussi, les composés de Zn2+ favorisent l'expression de VEGF-A, en stimulant sa transcription. L'étude de l'impact d'une stabilisation des G-quadruplexes sur la polarisation des macrophages a montré que les composés de nickel promeuvent la polarisation des macrophages naïfs vers un phénotype anticancéreux M1, tout en inhibant l'acquisition de marqueurs pro-tumoraux de type M2.L'ensemble de nos résultats démontre le fort potentiel de nos complexes métalliques en tant que stabilisateurs de G-quadruplexes, présentant de prometteuses propriétés anticancéreuses, notamment en modulant le microenvironnement tumoral. Ces résultats ouvrent la possibilité à de nombreuses perspectives d'investigation, suggérant de nouvelles pistes thérapeutiques en cancérologie
Triple-negative breast cancer and pancreatic adenocarcinoma are associated to very low survival-rates due to their high resistance to conventional treatments, posing significant public healthiness issue. The development of new targeted therapeutic options is then crucial. G-rich sequences in nucleic acids can form non-conventional secondary structures, known as G-quadruplexes, identified in telomeric sequences and in the promoters of potent oncogenes, such as cMYC, cKIT, and BCL2. These structures play a critical role in regulating gene expression, making them as promising therapeutic targets in cancer treatment.In this study, we employed a transdisciplinary approach, integrating chemical synthesis, molecular dynamic simulations, and cellular and molecular biology, to identify novel G-quadruplex binders and stabilizers aimed at controlling cancer progression. Previous work in our laboratory demonstrated that symmetric planar metal complexes could specifically bind these structures. In that sense, we synthesized 12 new transition metal complexes of Zn2+, Ni2+, Cu2+, Pd2+ and Pt2+, from the Salphen scaffold. Their ability to selectively bind and stabilize G-quadruplexes over double-stranded DNA were confirmed. Molecular dynamic simulations revealed an unconventional binding mode involving interaction with the G-quadruplex loop.Immunofluorescence assays confirmed that the compounds enhance G-quadruplex formation, in cancer cell lines, leading to the early downregulation of several G-quadruplex-driven oncogenes, such as kRAS, RET, and cMYC. This downregulation reduced cancer cell proliferation and viability, with less effect on non-cancerous cells.Some complexes induced apoptosis in cancer cells without affecting the non-neoplastic cells, after decreased hRAS and cMYC transcript levels, while other compounds caused DNA damage in pancreatic cancer cells T3M4. Notably, Zn2+ compounds increased VEGF-A expression, enhancing its transcription. We also investigated the effects of G-quadruplex stabilization on macrophages polarization, showing that nickel compounds promoted the polarization of M0 macrophages towards the anticancer M1 phenotype, while inhibiting the acquisition of pro-tumoral M2 markers.Overall, our novel metal complexes demonstrate significant potential in stabilizing G-quadruplex and exhibit promising anticancer properties, including modulation of the tumor microenvironment. These preliminary results suggest avenues for further research, with potential implications for advancing strategies in cancer therapy

Targeting DNA has the advantage over proteins for cancer remediation because of the fewer copies of the ligands required for the desired therapeutic effect. Traditionally, covalent DNA binders like alkylating agents have been used to induce genetic instability through the formation of DNA lesions and strand breaks, leading to cellular apoptosis. The primary drawback of this treatment is the non-specific binding that affects both cancerous and non-cancerous cells. G-quadruplexes are the DNA secondary structures that are present in abundance near the promoter regions of the oncogenes and are involved in the regulation of their activities. A ligand-mediated stabilization of G-quadruplexes in the promoter regions and down-regulation of the associated oncogenes have been validated. In contrast to alkylating agents, G-quadruplex ligands induce genetic stabilization through non-covalent interactions. They can be designed to interact specifically with G-quadruplex DNA over duplex DNA, which reduce side effects arising from the off-targeting. G-quadruplex ligands invariably have the large planar aromatic moiety to interact with G-quadruplexes through π- π stacking interactions. For determining the size effect of the aromatic moiety on stabilization of G-quadruplexes, a series of ligands were synthesized by conjugating nucleobases or 1,10-phenanthroline with an aminoglycoside, neomycin. The resulting conjugates increased the binding affinity synergistically and enabled us to study the effect of the stacking moiety required for G-quadruplex stabilization. Nucleobase-neomycin conjugates did not show stabilization stabilize of human telomeric G-quadruplex. 1,10-Phenanthroline-neomycin conjugate (7b) on the other hand binds to human telomeric G-quadruplex with a Ka of (8.92.4)×108 M-1 and inhibits telomerase activity at 1.56 µM probably through G-quadruplex stabilization. Moving forward, we further enlarged the aromatic moiety by tethering two 1,10-phenantholine molecules together through a five-atom linker. The resulting molecule (2-Clip-phen) was conjugated with various amino-containing side chains. 2-Clip-phen derivatives showed at least 30 times weaker binding to duplex DNA over G-quadruplex DNA. In addition, compounds showed a preference for the antiparallel G-quadruplex conformation over parallel and hybrid G-quadruplex conformations, as shown in the CD spectroscopy studies. Ligands 11 and 13 induced the formation of an antiparallel G-quadruplex from random coils and stabilize it to 60 oC (Tm) in a salt-free condition. Mass spectrometry study showed the formation of a two-tetrad G-quadruplex with the 2-Clip-phen ligand. Docking study showed that the ligand interacts most favorably with antiparallel G-quadruplex conformation, which is supported further by the larger thermal stabilization effect on antiparallel G-quadruplex compared with other G-quadruplex conformations. Our study suggests that 2-Clip-phen can be used as a scaffold for designing G-quadruplex binding ligands that preferentially bind to antiparallel G-quadruplexes, which has never been reported before.

In addition to the Watson and Crick B-form duplex DNA, G-quadruplexes are four-stranded DNA structures formed in vivo by the self-assembly of guanine-rich sequences. These can be formed by one, two or four separate strands of DNA and present a diversity of topologies, defined by the strand orientation, loop size and sequence. G-quadruplexes can be found in telomeres, immunoglobulin switch regions and gene promoter regions. The biological relevant location on the genome makes these high-order structures an attractive target for drug design and the development of highly specific ligands that bind and stabilize G-quadruplex with therapeutic activity. Herein, the biosynthesis of a novel G-rich quadruplex-forming DNA sequence 58Sγ3 is described by plasmid amplification. The recovery and purification of 58Sγ3 oligonucleotide using size-exclusion chromatography is presented. The G-quadruplex formation is promoted and its topology is determined by circular dichroism. The stabilization of the G-quadruplex structure with quinoline and naphthalene-based derivatives is studied using melting analysis, G4-FID and PCR-stop assays. The results suggest that 58Sγ3 folds into a parallel-stranded G-quadruplex structure in 500 mM KCl buffer and that naphthalene-based ligands bind and stabilize the G-quadruplex structure. The ligands are also found to be quadruplex-specific over duplex DNA and inhibit Taq DNA polymerase. This work provides evidence for G-quadruplex formation within the immunoglobulin switch regions. Furthermore, it is suggested that the novel ligands here reported act as potent specific G-quadruplex binders and may also potentially be used to inhibit genes transcription in tumor cells.
Além da forma B Watson e Crick do ADN duplex, os G-quadruplexes são estruturas de ADN de quatro cadeias, formadas in vivo pela auto-associação de sequências ricas em guaninas. Estas podem ser formadas por uma, duas ou quatro cadeias distintas de ADN e apresentar uma diversidade de topologias, definidas pela orientação da cadeia, tamanho dos loops e a sequência. G-quadruplexes podem ser encontrados nos telómeros, regiões de troca das imunoglobulinas e nas regiões dos promotores génicos. A localização biologicamente relevante no genoma faz com que estas estruturas altamente ordenadas sejam um alvo atrativo do desenho de fármacos e o desenvolvimento de ligandos altamente específicos que ligam e estabilizam o G-quadruplex com ação terapêutica. Neste trabalho, descreve-se a biossíntese da nova sequência de ADN rica em guaninas e formadora de G-quadruplex 58Sγ3, utilizando amplificação por plasmídeo. A recuperação e purificação do oligonucleótido 58Sγ3 é efetuada por cromatografia de exclusão molecular. A formação de G-quadruplex é promovida e a sua topologia é determinada por dicroísmo circular. A estabilização da estrutura do G-quadruplex com ligandos derivados de quinolina e naftaleno é estudada utilizando ensaios de estabilização térmica no dicroísmo circular, G4-FID e PCR-stop. Os resultados sugerem que 58Sγ3 adota uma estrutura G-quadruplex paralela em tampão 500 mM KCl e que os ligandos de naftaleno ligam e estabilizam a estrutura do G-quadruplex. Os ligandos demonstraram também ser específicos do G-quadruplex em relação ao ADN duplex além de inibir a Taq ADN polimerase. Este trabalho fornece evidência da formação de G-quadruplex nas regiões de troca das imunoglobulinas. Além disso, sugere que os derivados de naftaleno atuam como ligandos do G-quadruplex e que podem ser potencialmente utilizados para inibir a transcrição de genes em células tumorais.